BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

...small molecule inhibitor CA-170 (CA-170) from Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) and Curis Inc. (NASDAQ:CRIS). CA-170...
BioCentury | Jul 19, 2018
Tools & Techniques

Immunotherapy Matchmaking

...programs, according to BioCentury’s BCIQ database. Aurigene Discovery Technologies Ltd. and partner Curis Inc. have CA-170...
BioCentury | May 6, 2017
Product Development

Finding gems in India

...license and option agreement for immuno-oncology and precision oncology compounds. The most advanced compound is CA-170...
...Orion Corp. (HSE:ORNAV; HSE:ORNBV), Espoo, Finland References Ward, M. “Metabolic drive.” BioCentury (2010) Emily Cukier-Meisner, Senior Writer CA-170 ODM-207 Agios...
BioCentury | Mar 31, 2017
Targets & Mechanisms

Cells on the rise

...for VISTA as a single target, but Aurigene Discovery Technologies Ltd. and Curis Inc. have CA-170...
BioCentury | Mar 30, 2017
Clinical News

Paper: Targeting VISTA may benefit prostate cancer patients

...is the first to link VISTA to prostate cancer in the post-Yervoy setting. Small molecule CA-170...
...study to treat advanced solid tumors and lymphomas. Bristol-Myers Squibb Co. (NYSE:BMY) markets Yervoy. Jaime De Leon CA-170 ipilimumab Yervoy Bristol-Myers...
BioCentury | Sep 12, 2016
Company News

Aurigene, Curis deal

...Aurigene owns about a 19.6% stake in Curis. Curis’ lead compound under the deal is CA-170...
BioCentury | Jul 11, 2016
Clinical News

CA-170: Phase I started

...Curis began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate once-daily oral CA-170 in...
...Aurigene Discovery Technologies Ltd. , Bangalore, India Curis Inc. (NASDAQ:CRIS), Lexington, Mass. Product: CA-170 (formerly AUPM-170...
BioCentury | Oct 26, 2015
Company News

Aurigene, Curis deal

...programs from Aurigene to treat cancer and cytokine-driven inflammatory and autoimmune diseases. The programs include CA-170...
...deal. In 1H16, Curis plans to submit an IND and begin Phase I testing of CA-170...
Items per page:
1 - 8 of 8